Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

被引：24

作者：

Wierda, William G. ^{[1
]}

Lewis, David John ^{[2
]}

Ghia, Paolo ^{[3
,4
]}

Shah, Nirav N. ^{[5
]}

Coombs, Catherine C. ^{[6
]}

Cheah, Chan Y. ^{[7
,8
]}

Lamanna, Nicole ^{[9
]}

Rhodes, Joanna M. ^{[10
]}

Hoffmann, Marc ^{[11
]}

Ma, Shuo ^{[12
]}

Eyre, Toby A. ^{[13
]}

Munir, Talha ^{[14
]}

Patel, Manish R. ^{[15
]}

Alencar, Alvaro J. ^{[16
]}

Tam, Constantine S. ^{[17
,18
]}

Seymour, John F. ^{[19
]}

Jurczak, Wojciech ^{[20
]}

Lech-Maranda, Ewa ^{[21
]}

Roeker, Lindsey E. ^{[22
]}

Thompson, Philip A. ^{[1
]}

Abada, Paolo B. ^{[23
]}

Wang, Chunxiao ^{[24
]}

Nair, Binoj ^{[23
]}

Liu, Hui ^{[23
]}

Tsai, Donald E. ^{[23
]}

Mato, Anthony R. ^{[22
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Plymouth Hosp NHS Trust, Derriford Hosp, Plymouth, Devon, England

[3] Univ Vita Salute San Raffaele, Milan, Italy

[4] IRCCS Osped San Raffaele, Milan, Italy

[5] Med Coll Wisconsin, Brookfield, WI USA

[6] Univ N Carolina, Chapel Hill, NC 27515 USA

[7] Linear Clin Res, Perth, WA, Australia

[8] Sir Charles Gairdner Hosp, Perth, WA, Australia

[9] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York Presbyterian, New York, NY USA

[10] Northwell Hlth Canc Inst, New Hyde Pk, NY USA

[11] Univ Kansas, Ctr Canc, Kansas City, KS USA

[12] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL USA

[13] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[14] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[15] Sarah Cannon Res Inst, Sarasota, FL USA

[16] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA

[17] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[18] Univ Melbourne, Melbourne, Vic, Australia

[19] Univ Melbourne, Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[20] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[21] Inst Hematol & Transfus Med, Warsaw, Poland

[22] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[23] Loxo Lilly, Indianapolis, IN USA

[24] Eli Lilly & Co, Indianapolis, IN 46285 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157058

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Mato, Anthony
Cheah, Chan Yoon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 11 - 12
[22] Pirtobrutinib, a Next-Generation, Highly Selective, Noncovalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
[23] Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18Month Median Survival Follow-up from the Phase 1/2 BRUIN Study
Wierda, William G.
Shah, Nirav N.
Cheah, Chan Yoon
Lewis, David
Hoffmann, Marc S.
Coombs, Catherine C.
Lamanna, Nicole
Ma, Shuo
Jagadeesh, Deepa
Munir, Talha
Wang, Yucai
Eyre, Toby A.
Rhodes, Joanna M.
McKinney, Matthew
Lech-Maranda, Ewa
Tam, Constantine S.
Jurczak, Wojciech
Izutsu, Koji
Alencar, Alvaro J.
Patel, Manish
Seymour, John F.
Woyach, Jennifer A.
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo
Ho, Caleb
Marella, Narasimha
Wang, Chunxiao
Ruppert, Amy S.
Nair, Binoj Chandrasekharan
Liu, Hui
Tsai, Donald E.
Ghia, Paolo
BLOOD, 2023, 142
[24] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study
Eyre, Toby
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Woyach, Jennifer
Wierda, William G.
Cheah, Chan Y.
Roeker, Lindsey
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David
Gerson, James N.
Alencar, Alvaro
Taylor, Justin
Abedel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 37 - 38
[25] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study
Eyre, Toby
Shah, Nirav N.
Alencar, Alvaro
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine C.
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal A.
Ghia, Paolo
Yin, Ming
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 142 - 143
[26] Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
Shah, Nirav N.
Wang, Michael L.
Brown, Jennifer R.
Patel, Krish
Woyach, Jennifer A.
Wierda, William G.
Ujjani, Chaitra S.
Eyre, Toby A.
Zinzani, Pier Luigi
Alencar, Alvaro J.
Gastinne, Thomas
Ghia, Paolo
Lamanna, Nicole
Hoffmann, Marc
Patel, Manish R.
Flinn, Ian W.
Gerson, James N.
Ma, Shuo
Coombs, Catherine C.
Cheah, Chan Y.
Lech-Maranda, Ewa
Fakhri, Bita
Kim, Won-Seog
Barve, Minal A.
Cohen, Jonathon B.
Jurczak, Wojciech
Munir, Talha
Thompson, Meghan C.
Roeker, Lindsey E.
Bao, Katherine
Cangemi, Nicholas A.
Kherani, Jennifer F.
Walgren, Richard A.
Han, Hongmei
Ruppert, Amy S.
Mato, Anthony R.
BLOOD, 2022, 140 : 4127 - 4132
[27] Pirtobrutinib in Relapsed/Refractory CLL/SLL: Results From BTK-Naive Cohort in the Phase 1/2 BRUIN Study
Wierda, William G.
Eyre, Toby A.
Lech-Maranda, Ewa
Roeker, Lindsey E.
Patel, Manish
Fukuhara, Noriko
Woyach, Jennifer A.
Brown, Jennifer R.
Patel, Krish
Tam, Constantine S.
Fahkri, Bita
Abada, Paolo
Tsai, Donald E.
Sizelove, Richard
Jurczak, Wojciech
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S350 - S350
[28] LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Mato, Anthony
Cheah, Chan Yoon
BLOOD, 2020, 136
[29] Efficacy of Pirtobrutinib in BTK-Inhibitor Pre-treated Relapsed/ Refractory CLL/SLL: Phase 1/2 BRUIN Study Results by Prior BCL2-Inhibitor Therapy
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Roeker, Lindsey E.
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John
Shah, Nirav N.
Ujjani, Chaitra
Fahkri, Bita
Coombs, Catherine C.
Flinn, Ian
Patel, Manisha R.
Nasta, Sunita D.
Cohen, Jonathon B.
Alencar, Alvaro J.
Cheah, Chan Y.
Ma, Shuo
Rhoades, Joanna M.
Jagadeesh, Deepa
Zinzani, Pier Luigi
Osterborg, Anders
Izutsu, Koji
Tsai, Donald E.
Abada, Paolo
Balbas, Minna
Ruppert, Amy S.
Li, Jian
Jurczak, Wojciech
Wierda, William G.
Stilgenbauer, Stephan
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 118 - 119
[30] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 13 - 14

← 1 2 3 4 5 →